SLC5A2 and hydrops fetalis: There are also conflicting results on the incidence of VAs in patients receiving SGLT2-i; in fact, a recent meta-analysis found no association between SGLT2i therapy and lower VAs in patients with T2DM and/or HF and/or chronic kidney disease (34).